Health Business Investing

Buy, Sell, or Hold? Insiders Bet on 3 Healthcare Stocks

Pinterest LinkedIn Tumblr
Advertiser Disclosure

This article may contain references to products or services from one or more of our advertisers or partners. We may receive compensation when you click on links to those products or services. Nonetheless, our opinions are our own.

The information presented in this article is accurate to the best of our knowledge at the time of publication. However, information is subject to change, and no guarantees are made about the continued accuracy or completeness of this content after its publication date.

add FangWallet as a Google Preferred Source por favor

The healthcare sector has been one of the most active parts of the stock market for a long time. The industry is important for the economy and for people’s health. It is responsible for everything from new discoveries in biotechnology to the growth of telehealth and high-tech medical devices. In 2025, healthcare stocks will still be very interesting because they are linked to global issues, an aging population, and rapid technological progress.

But the industry is also very unstable. Share prices can go up or down in just a few days because of changes in rules, problems with clinical trials, or changes in prices. As a result, many investors prefer to wait for clearer indicators before making a decision. One of the most closely watched signs is when executives or directors buy shares of their own company.

What Insider Buying Means in Healthcare

Insider buying occurs when company executives, directors, or other individuals with access to non-public information purchase shares of their own company.

Why It Matters: Insiders typically know the business fundamentals better than anyone else. When they buy, it often signals confidence in growth prospects.

Legal Context: Reported insider buying is legal and open, unlike illegal insider trading that is based on secret information. Companies tell the Securities and Exchange Commission (SEC) about these kinds of deals, which makes them available to investors.

Differences Between Legal Insider Buying and Illegal Insider Trading

AspectLegal Insider BuyingIllegal Insider Trading
Information BasisPublicly disclosed after purchaseBased on nonpublic, material information
LegalityLegal if reported to regulatorsIllegal and subject to penalties
Investor UseConfidence signalMarket manipulation

Eli Lilly & Co. (LLY)

Sector Focus: Drug development for chronic conditions
Recent Insider Activity: Significant insider share purchases

Eli Lilly is working on a promising line of drugs that will help people with long-term health problems like diabetes and heart disease. In 2025, the stock market fell sharply, with the worst single-day drop in more than 20 years. Several executives bought a total of $2.9 million worth of stock. David Ricks, the CEO, bought more than $1 million, and other board members did too.

Catalysts

  • Pipeline Strength: Multiple late-stage drug candidates with strong trial results
  • Revenue Outlook: Potential for billions in annual sales if approvals succeed
  • Competitive Position: Leading role in chronic disease treatment

Investment Implication: Insider activity suggests optimism. However, investors must remain aware of risks tied to regulatory approval timelines and potential competition.

UnitedHealth Group (UNH)

Sector Focus: Healthcare and digital platforms through Optum
Recent Insider Activity: Large insider purchases during leadership transition

Stephen Hemsley, who was CEO again in May 2025, bought 86,700 shares for about $25 million. Many directors and CFO John Rex also bought millions of dollars’ worth of stock. This sudden increase in insider activity shows that people believe in the company’s long-term growth, especially in digital health, insurance partnerships, and telehealth expansion.

Catalysts

  • Post-Pandemic Growth: Continued double-digit adoption of telehealth and digital healthcare services
  • Innovation: AI-driven diagnostics, cybersecurity, and user-friendly interfaces through Optum
  • Market Expansion: Strong insurer and hospital partnerships ensure broader reach

Investment Implication: Insider confidence matches strong trends in industry growth. Still, competition from well-known tech companies and ongoing regulatory scrutiny could put pressure on prices.


Voted "Best Overall Budgeting App" by Forbes and WSJ

Monarch Money helps you budget, track spending, set goals, and plan your financial future—all in one app.

Get 50% OFF your first year with code MONARCHVIP


Medtronic plc (MDT)

Sector Focus: Surgical instruments and diagnostic systems
Recent Insider Activity: Ramp-up of insider purchases after FDA approvals

Medtronic makes high-tech medical devices and diagnostic tools. In the third quarter of 2025, executives, including CEO Geoffrey Martha, bought more than $2.3 million worth of stock on the open market. This came after the FDA gave its approval and hospitals signed contracts for several years, which is a sign of long-term hope.

Catalysts

  • Regulatory Wins: FDA approvals provide near-term sales momentum
  • Hospital Contracts: Multi-year agreements ensure steady demand
  • Innovation-Safety Balance: Strong emphasis on product performance and patient safety

Investment Implication: People who work for the company expect steady revenue growth. Regulatory issues are still a problem, but established contracts make things less volatile than with other biotech companies.

Comparative Snapshot of Insider Activity

CompanySectorInsider Buying SignalStrengthsRisks
Eli Lilly (LLY)PharmaceuticalsHighStrong drug pipeline, revenue potentialClinical trial and approval risks
UnitedHealth (UNH)Telehealth & ServicesHighExpanding demand, partnershipsCompetitive pressure, regulation
Medtronic (MDT)Medical DevicesHighFDA approvals, hospital contractsRegulatory scrutiny, manufacturing risks

Conclusion

Healthcare is still one of the most promising but unpredictable areas to invest in. When backed by strong fundamentals, insider buying can give you important information, but it should never be the only thing you use to make decisions.

  • Eli Lilly: Highlights the transformative potential of pharmaceuticals.
  • UnitedHealth: Shows how digital adoption continues to reshape healthcare delivery.
  • Medtronic: Demonstrates the resilience of medical device companies through contracts and approvals.

The lesson for investors is clear: insider activity can help you find your way, but it can’t show you where to go. To be successful, you need to combine this signal with careful research, risk assessment, and portfolio diversification. There will be a lot of chances and risks as healthcare innovation speeds up in 2025. The best thing to do is still to stay informed and follow the rules.

Frequently Asked Questions

What does insider buying in healthcare stocks signal?

When company insiders buy stock, it usually means that they believe in the company’s long-term future. In healthcare, this could mean trust in the results of clinical trials, product approvals, or plans for growth.

How reliable is insider buying as an investment signal?

It is a strong sign, but not a sure thing. Insiders can be wrong, and outside factors like changes in regulations or competition can also affect performance.

Which healthcare sectors show the most insider activity in 2025?

Recent activity has mostly been in pharmaceuticals, digital health, and medical devices. This is because there are new drugs, telehealth platforms, and FDA-approved technologies being developed all the time.

What risks should I consider when investing in healthcare stocks?

Some of the biggest risks are changes in regulations, failed clinical trials, product recalls, cyber threats, and fierce competition.

Where can I track insider buying activity?

Investors can look at insider buying disclosures on the SEC’s EDGAR database, in financial news articles, or on websites that track stocks.

How do healthcare insider buys compare with other industries?

In healthcare, insider buying often has a bigger effect because getting regulatory approvals and making scientific breakthroughs are so important. Small changes can have a big effect on valuations in sectors other than consumer goods.

Is 2025 a good year to invest in healthcare stocks?

Healthcare is still appealing because of global health problems and new ideas that are driving demand. But managing risk and timing are very important. Insider buying can help the outlook, but it’s important to have a balanced mix of investments.


Join a vibrant community with the sole mission to achieve financial independence.



Trusted, Edited and Reviewed Original Source Content. Secured by FangWallet

Reviewed and edited by Albert Fang.

See a typo or want to suggest an edit/revision to the content? Use the contact us form to provide feedback.

At FangWallet, we value editorial integrity and open collaboration in curating quality content for readers to enjoy. Much appreciated for the assist.


Did you like our article and find it insightful? We encourage sharing the article link with family and friends to benefit as well - better yet, sharing on social media. Thank you for the support! 🍉

Article Title: Buy, Sell, or Hold? Insiders Bet on 3 Healthcare Stocks

https://fangwallet.com/2025/09/13/buy-sell-or-hold-insiders-bet-on-3-healthcare-stocks/


The FangWallet Promise

FangWallet is an editorially independent resource - founded on breaking down challenging financial concepts for anyone to understand since 2014. While we adhere to editorial integrity, note that this post may contain references to products from our partners.

The FangWallet promise is always to have your best interest in mind and be transparent and honest about the financial picture.



Become an Insider

FangWallet's Verified Budget Planner Template Printable

Subscribe to get a free daily budget planner printable to help get your money on track!

Make passive money the right way. No spam.

* indicates required

Intuit Mailchimp


Editorial Disclaimer: The editorial content on this page is not provided by any of the companies mentioned. The opinions expressed here are the author's alone.

The content of this website is for informational purposes only and does not represent investment advice, or an offer or solicitation to buy or sell any security, investment, or product. Investors are encouraged to do their own due diligence, and, if necessary, consult professional advising before making any investment decisions. Investing involves a high degree of risk, and financial losses may occur including the potential loss of principal.


Write for Us


Source Citation References:

+ Inspo

There are no additional citations or references to note for this article at this time.


Mei Ling is an award-winning personal finance author whose work has inspired countless individuals to take charge of their financial health. Their expertise spans diverse areas, including passive income generation, real estate investment, and optimizing retirement portfolios.

Write A Comment

Pin It